Ubs Asset Management Americas Inc Catalyst Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 526,297 shares of CPRX stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
526,297
Previous 263,905
99.43%
Holding current value
$12.8 Million
Previous $5.51 Million
131.74%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$455 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$207 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$135 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$83.2 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$76.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.5B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...